)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Elicera Therapeutics
Elicera Therapeutics (ELIC) investor relations material
Elicera Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary13 Feb, 2026
Executive summary
Achieved significant clinical progress, notably in the CARMA study for B-cell lymphoma, with 4 out of 6 patients in early cohorts showing complete metabolic response and no serious adverse events reported.
Completed Phase I/II trial for ELC-100 in neuroendocrine tumors, demonstrating good safety and early efficacy signals, including partial responses in two of eight evaluable patients.
Advanced preclinical programs, especially ELC-401 for glioblastoma, and continued efforts to secure financing and strategic partnerships.
Increased international visibility through scientific presentations and collaborations.
Financial highlights
Operating loss for Q4 2025 was SEK -7.1 million, compared to SEK -2.9 million in Q4 2024; full-year operating loss was SEK -17.9 million, up from SEK -16.9 million in 2024.
Loss for Q4 2025 was SEK -7.0 million (Q4 2024: SEK -2.6 million); full-year loss was SEK -17.4 million (2024: SEK -16.1 million).
Cash flow from operating activities for Q4 2025 was SEK -10.1 million (Q4 2024: SEK -4.2 million); full-year cash flow from operations was SEK -21.6 million (2024: SEK -23.5 million).
Cash and cash equivalents at year-end were SEK 24.8 million (2024: SEK 26.4 million).
Earnings per share for the year were SEK -0.38 (2024: SEK -0.51).
Outlook and guidance
Next data update from the CARMA study, including the highest dose group, is planned for Q2 2026.
Strategic options for further development of ELC-100 are under evaluation following positive Phase I/II results.
Advisory meeting with Swedish Medical Products Agency planned for ELC-401 in spring 2026; clinical studies may start in 2027.
Continued focus on securing grants and partnerships to fund preclinical and clinical programs.
CARMA: Efficacy in relapsed CD19-CAR T patients?
iTANK licensing: What's needed for a deal?
ELC-100 program: Strategic options evaluation
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Elicera Therapeutics earnings date
Q1 20265 May, 2026
Elicera Therapeutics
Next Elicera Therapeutics earnings date
Q1 20265 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The company focuses on developing next-generation cell and gene therapies aimed at treating cancer through immune-based approaches. Elicera's pipeline includes four main drug candidates, two of which are in the field of oncolytic viruses and two in CAR T-cell therapies. Their proprietary iTANK (ImmunoTherapies Activated with Nap for efficient Killing) platform is designed to enhance the efficacy of these therapies. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Nasdaq Stockholm.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage